Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fiona Lalloo

Showing results (31-40 of 162) with videos related to

Pageof 17
Sort By:
Journal of Medical Genetics|May 30, 2024
Carrier testing for partners of <i>MUTYH</i> variant carriers: UK Cancer Genetics Group recommendationsTerri Patricia McVeigh, Fiona Lalloo, Kevin J Monahan, et al.
Journal of Medical Genetics|May 2, 2024
Challenges in developing and implementing international best practice guidance for intermediate-risk variants in cancer susceptibility genes: <i>APC</i> c.3920T>A p.(Ile1307Lys) as an exemplarTerri Patricia McVeigh, Fiona Lalloo, Ian M Frayling, et al.
Journal of Medical Genetics|February 28, 2018
Penetrance estimates for <i>BRCA1</i>, <i>BRCA2</i> (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?D Gareth Evans, Emma Woodward, Elaine F Harkness, et al.
Breast Cancer Research : BCR|December 26, 2006
Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriersAntonis C Antoniou, Andrew Shenton, Eamonn R Maher, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 28, 2022
High detection rate from genetic testing in BRCA-negative women with familial epithelial ovarian cancerNicola Flaum, Emma J Crosbie, Richard Edmondson, et al.
BMJ Oncology|March 6, 2025
UK-based clinical testing programme for somatic and germline BRCA1/2, ATM and CDK12 mutations in prostate cancer: first resultsD Gareth Evans, George Burghel, Helene Schlecht, et al.
Journal of Medical Genetics|April 12, 2024
Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyond <i>BRCA2, BRCA1</i> and <i>CHEK2</i>D Gareth Evans, George J Burghel, Sacha J Howell, et al.
Journal of Medical Genetics|May 2, 2020
Uptake of pre-symptomatic testing for <i>BRCA1</i> and <i>BRCA2</i> is age, gender, offspring and time-dependentClaire Forde, Kate Brunstrom, Emma Woodward, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 7, 2024
Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapyD Gareth Evans, Robert D Morgan, Emma J Crosbie, et al.
Breast Cancer Research : BCR|November 26, 2015
Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk womenD Gareth Evans, Julie Wisely, Tara Clancy, et al.
Pageof 17

Showing results (31-40 of 162) with videos related to

Sort By:
Pageof 17
Journal of Medical Genetics|May 30, 2024
Carrier testing for partners of <i>MUTYH</i> variant carriers: UK Cancer Genetics Group recommendationsTerri Patricia McVeigh, Fiona Lalloo, Kevin J Monahan, et al.
Journal of Medical Genetics|May 2, 2024
Challenges in developing and implementing international best practice guidance for intermediate-risk variants in cancer susceptibility genes: <i>APC</i> c.3920T>A p.(Ile1307Lys) as an exemplarTerri Patricia McVeigh, Fiona Lalloo, Ian M Frayling, et al.
Journal of Medical Genetics|February 28, 2018
Penetrance estimates for <i>BRCA1</i>, <i>BRCA2</i> (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?D Gareth Evans, Emma Woodward, Elaine F Harkness, et al.
Breast Cancer Research : BCR|December 26, 2006
Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriersAntonis C Antoniou, Andrew Shenton, Eamonn R Maher, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 28, 2022
High detection rate from genetic testing in BRCA-negative women with familial epithelial ovarian cancerNicola Flaum, Emma J Crosbie, Richard Edmondson, et al.
BMJ Oncology|March 6, 2025
UK-based clinical testing programme for somatic and germline BRCA1/2, ATM and CDK12 mutations in prostate cancer: first resultsD Gareth Evans, George Burghel, Helene Schlecht, et al.
Journal of Medical Genetics|April 12, 2024
Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyond <i>BRCA2, BRCA1</i> and <i>CHEK2</i>D Gareth Evans, George J Burghel, Sacha J Howell, et al.
Journal of Medical Genetics|May 2, 2020
Uptake of pre-symptomatic testing for <i>BRCA1</i> and <i>BRCA2</i> is age, gender, offspring and time-dependentClaire Forde, Kate Brunstrom, Emma Woodward, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 7, 2024
Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapyD Gareth Evans, Robert D Morgan, Emma J Crosbie, et al.
Breast Cancer Research : BCR|November 26, 2015
Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk womenD Gareth Evans, Julie Wisely, Tara Clancy, et al.
Pageof 17